Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan vs Valsartan in Hypertension After Missed Dose
NCT02242318Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2001
- Primary completion
- Sep 2002
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of telmisartan in hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in 24 hour mean Diastolic blood pressure (DBP) after a missed dose at Day 55 and Change in mean DBP during the last 6 hours of the 24 hour dosing interval at 8 weeks. Started Sep 2001; status: completed.
02
Drugs
telmisartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02242318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242318.